Sean Iwamoto

Dr. Sean Iwamoto


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2019 in Obesity
Verified
Journal Article
Closed access
PDF file
DSDavid R. Saxon
David R. Saxon
SISean Iwamoto
Sean Iwamoto
CMChristie J. Mettenbrink
Christie J. Mettenbrink
EMEmily McCormick
Emily McCormick
DADavid Arterburn
David Arterburn
DBDaniel H. Bessesen
Daniel H. Bessesen

12 February 2020 in International Journal of Transgender Health
Verified
Journal Article
Closed access
JDJustine Defreyne
Justine Defreyne
YVYuran Vanwonterghem
Yuran Vanwonterghem
SCSarah Collet
Sarah Collet
SISean Iwamoto
Sean Iwamoto
CWChantal M. Wiepjes
Chantal M. Wiepjes
GTGuy T’sJoen
Guy T’sJoen
Background: Previous studies have cross-sectionally described amenorrhea in cohorts of transgender men on intramuscular or subcutaneous testosterone injections. It remains uncertain which testosterone preparations most effectively suppress vaginal bleeding and when amenorrhea occurs after testosterone initiation. Aim:To investigate the clinical effects of various testosterone preparations on vaginal bleeding and spotting in transgender men. Methods: This prospective cohort study was part of the European Network for the Investigation of Gender Incongruence (ENIGI). Data on the persistence and intensity of vaginal bleeding and spotting, serum sex steroid levels and body composition were prospectively and cross-sectionally assessed in 267 transgender men during a three-year follow-up period, starting at the initiation of various testosterone preparations. Results: After three months of testosterone, 17.9% of transgender men reported persistent vaginal bleeding and 26.8% reported spotting. The percentages reporting vaginal bleeding and spotting decreased over the first year of testosterone (bleeding 4.7% and spotting 6.9% at 12 months, respectively), with no participants reporting vaginal bleeding or spotting after 18 months of testosterone. Factors associated with vaginal bleeding or spotting included lower serum testosterone levels and being on testosterone gel as compared to injections (e.g., esters or undecanoate preparations). If vaginal bleeding persisted, starting progestogens at three months resulted in a decrease in the intensity of vaginal bleeding and spotting. Discussion: Transgender men and hormone-prescribing providers can be reassured that vaginal bleeding and spotting usually stop within three months after testosterone initiation. If not, serum testosterone levels should be measured and testosterone dose adjusted to achieve serum testosterone levels in the physiologic male range. Adding a progestin can be considered after three to six months if bleeding persists. Providers should be aware that cessation of bleeding can be more difficult to achieve in transgender men with lower serum testosterone levels or those on testosterone gel.

1 June 2019 in Clinical & Translational Metabolism
Verified
Journal Article
Closed access
PDF file
MRMicol S. Rothman
Micol S. Rothman
SISean Iwamoto
Sean Iwamoto

1 January 2019 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
SISean Iwamoto
Sean Iwamoto
JDJustine Defreyne
Justine Defreyne
MRMicol S. Rothman
Micol S. Rothman
JSJudith Van Schuylenbergh
Judith Van Schuylenbergh
LBLaurens Van de Bruaene
Laurens Van de Bruaene
GTGuy T’sJoen
Guy T’sJoen
Transgender (trans) women (TW) were assigned male at birth but have a female gender identity or gender expression. The literature on management and health outcomes of TW has grown recently with more publication of research. This has coincided with increasing awareness of gender diversity as communities around the world identify and address health disparities among trans people. In this narrative review, we aim to comprehensively summarize health considerations for TW and identify TW-related research areas that will provide answers to remaining unknowns surrounding TW’s health. We cover up-to-date information on: (1) feminizing gender-affirming hormone therapy (GAHT); (2) benefits associated with GAHT, particularly quality of life, mental health, breast development and bone health; (3) potential risks associated with GAHT, including cardiovascular disease and infertility; and (4) other health considerations like HIV/AIDS, breast cancer, other tumours, voice therapy, dermatology, the brain and cognition, and aging. Although equally deserving of mention, feminizing gender-affirming surgery, paediatric and adolescent populations, and gender nonbinary individuals are beyond the scope of this review. While much of the data we discuss come from Europe, the creation of a United States transgender cohort has already contributed important retrospective data that are also summarized here. Much remains to be determined regarding health considerations for TW. Patients and providers will benefit from larger and longer prospective studies involving TW, particularly regarding the effects of aging, race and ethnicity, type of hormonal treatment (e.g. different oestrogens, anti-androgens) and routes of administration (e.g. oral, parenteral, transdermal) on all the topics we address.

5 February 2021 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
SISean Iwamoto
Sean Iwamoto
FGFrances Grimstad
Frances Grimstad
MIMichael S. Irwig
Michael S. Irwig
MRMicol S. Rothman
Micol S. Rothman

4 August 2021 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
SISean Iwamoto
Sean Iwamoto
LALayla A. Abushamat
Layla A. Abushamat
AZAdnin Zaman
Adnin Zaman
AMAnthony J. Millard
Anthony J. Millard
MCMarc-Andre Cornier
Marc-Andre Cornier